CL2013003550A1 - Compuestos derivados de (s)-n-(benzo-[d]-tiazol-2-il)-4-(5-(1,2-dihidroxietil)-piridin-2-il)-piperazin-1-carboxamida sustituidas; antagonistas de trpv1; composición farmacéutica; un producto de combinación; útiles para el tratamiento del dolor, osteoartritis, iu, úlcera, ibd ó ibs. - Google Patents

Compuestos derivados de (s)-n-(benzo-[d]-tiazol-2-il)-4-(5-(1,2-dihidroxietil)-piridin-2-il)-piperazin-1-carboxamida sustituidas; antagonistas de trpv1; composición farmacéutica; un producto de combinación; útiles para el tratamiento del dolor, osteoartritis, iu, úlcera, ibd ó ibs.

Info

Publication number
CL2013003550A1
CL2013003550A1 CL2013003550A CL2013003550A CL2013003550A1 CL 2013003550 A1 CL2013003550 A1 CL 2013003550A1 CL 2013003550 A CL2013003550 A CL 2013003550A CL 2013003550 A CL2013003550 A CL 2013003550A CL 2013003550 A1 CL2013003550 A1 CL 2013003550A1
Authority
CL
Chile
Prior art keywords
dihydroxyethyl
ibs
ibd
piperazin
thiazol
Prior art date
Application number
CL2013003550A
Other languages
English (en)
Inventor
Laykea Tafesse
Shigeru Ando
Noriyuki Kurose
Original Assignee
Purdue Pharma Lp
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46513798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003550(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Purdue Pharma Lp, Shionogi & Co filed Critical Purdue Pharma Lp
Publication of CL2013003550A1 publication Critical patent/CL2013003550A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255Tartaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2013003550A 2011-06-22 2013-12-11 Compuestos derivados de (s)-n-(benzo-[d]-tiazol-2-il)-4-(5-(1,2-dihidroxietil)-piridin-2-il)-piperazin-1-carboxamida sustituidas; antagonistas de trpv1; composición farmacéutica; un producto de combinación; útiles para el tratamiento del dolor, osteoartritis, iu, úlcera, ibd ó ibs. CL2013003550A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161499989P 2011-06-22 2011-06-22

Publications (1)

Publication Number Publication Date
CL2013003550A1 true CL2013003550A1 (es) 2014-11-14

Family

ID=46513798

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003550A CL2013003550A1 (es) 2011-06-22 2013-12-11 Compuestos derivados de (s)-n-(benzo-[d]-tiazol-2-il)-4-(5-(1,2-dihidroxietil)-piridin-2-il)-piperazin-1-carboxamida sustituidas; antagonistas de trpv1; composición farmacéutica; un producto de combinación; útiles para el tratamiento del dolor, osteoartritis, iu, úlcera, ibd ó ibs.

Country Status (32)

Country Link
US (4) US9273043B2 (es)
EP (2) EP3173411B1 (es)
JP (1) JP5699251B2 (es)
KR (2) KR20150055094A (es)
CN (2) CN105693712A (es)
AR (1) AR086709A1 (es)
AU (1) AU2012273652B2 (es)
BR (1) BR112013032658A2 (es)
CA (1) CA2837178C (es)
CL (1) CL2013003550A1 (es)
CO (1) CO6852081A2 (es)
CY (1) CY1119111T1 (es)
DK (1) DK2723732T3 (es)
ES (1) ES2620528T3 (es)
HR (1) HRP20170507T1 (es)
HU (1) HUE031372T2 (es)
IL (1) IL229817A (es)
LT (1) LT2723732T (es)
ME (1) ME02609B (es)
MX (1) MX354015B (es)
MY (1) MY185061A (es)
PE (1) PE20141531A1 (es)
PL (1) PL2723732T3 (es)
PT (1) PT2723732T (es)
RS (1) RS55701B1 (es)
RU (1) RU2621708C2 (es)
SG (2) SG195136A1 (es)
SI (1) SI2723732T1 (es)
TW (1) TWI453205B (es)
UA (1) UA113288C2 (es)
WO (1) WO2012176061A1 (es)
ZA (1) ZA201400419B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2723732T (pt) * 2011-06-22 2017-02-17 Purdue Pharma Lp Antagonistas de trpv1 incluindo substituinte di-hidroxilo e suas utilizações
KR101933622B1 (ko) * 2012-10-09 2018-12-28 삼성전자주식회사 소포를 모니터링하기 위한 조성물, 키트 및 이를 이용하여 소포를 모니터링하는 방법
JP6528845B2 (ja) * 2015-07-31 2019-06-12 株式会社村田製作所 アンテナ整合回路、アンテナ回路、フロントエンド回路および通信装置
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе
CN113077942B (zh) * 2021-04-12 2021-12-17 西北工业大学 一种基于功率超声制备智能柔性导电薄膜及其应用

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4409229A (en) 1977-12-02 1983-10-11 Hoechst-Roussel Pharmaceuticals, Inc. Antidepressive and tranquilizing substituted 1,3-dihydrospiro[benzo(c)thiophene]s
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPH0680054B2 (ja) 1985-06-19 1994-10-12 吉富製薬株式会社 ピペリジン誘導体
JPS6289679U (es) 1985-11-22 1987-06-08
US4797419A (en) 1986-11-03 1989-01-10 Warner-Lambert Company Method of treating the symptoms of senile cognitive decline employing di- or trisubstituted urea cholinergic agents
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
DE3905364A1 (de) 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
SK281621B6 (sk) 1990-06-07 2001-05-10 Astrazeneca Ab Indolové deriváty, spôsob ich prípravy, farmaceutické kompozície s ich obsahom a ich použitie
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JP3191429B2 (ja) 1992-09-02 2001-07-23 富士通テン株式会社 電子機器の挿排装置
WO1994007867A1 (en) 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
DE4234295A1 (de) 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JP2606138Y2 (ja) 1993-04-20 2000-09-25 株式会社小松製作所 クラッチ作動圧力検出手段を備えたクラッチ油圧制御弁装置
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE19514313A1 (de) 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
ATE301457T1 (de) 1995-06-12 2005-08-15 Searle & Co Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
DE59610509D1 (de) 1995-09-07 2003-07-10 Hoffmann La Roche Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz
EP0861075A1 (en) 1995-11-13 1998-09-02 Albany Medical College Analgesic compounds and uses thereof
FR2744448B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
US5891889A (en) 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU715202B2 (en) 1996-04-03 2000-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
US5990107A (en) 1996-06-28 1999-11-23 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US5798360A (en) 1996-08-01 1998-08-25 Isis Pharmaceuticals, Inc. N-(aminoalkyl)- and/or N-(amidoalkyl)- dinitrogen heterocyclic compositions
FR2758327B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles arylpiperazines derivees de piperidine
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
CA2298540A1 (en) 1997-08-20 1999-02-25 David J. Julius Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
JPH11199573A (ja) 1998-01-07 1999-07-27 Yamanouchi Pharmaceut Co Ltd 5ht3受容体作動薬及び新規ベンゾチアゾール誘導体
ZA99607B (en) 1998-01-27 1999-07-27 Rhone Poulenc Rorer Pharma Substituted oxoazaheterocyclyl factor xa inhibitors.
EP0943683A1 (en) 1998-03-10 1999-09-22 Smithkline Beecham Plc Human vanilloid receptor homologue Vanilrep1
AU4685699A (en) 1998-06-19 2000-01-05 Eli Lilly And Company Preparation of heteroaryl compounds
AU4395399A (en) 1998-07-02 2000-01-24 Sankyo Company Limited Five-membered heteroaryl compounds
AU754529B2 (en) 1998-09-22 2002-11-21 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
JP2002535256A (ja) 1999-01-25 2002-10-22 スミスクライン・ビーチャム・コーポレイション 化合物および方法
GB9907097D0 (en) 1999-03-26 1999-05-19 Novartis Ag Organic compounds
AP2001002281A0 (en) 1999-04-01 2001-09-30 Pfizer Prod Inc Sorbitol dehydrogen inhibitors.
WO2000069816A1 (en) 1999-05-17 2000-11-23 Eli Lilly And Company Metabotropic glutamate receptor antagonists
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
DE19934799B4 (de) 1999-07-28 2008-01-24 Az Electronic Materials (Germany) Gmbh Chiral-smektische Flüssigkristallmischung und ihre Verwendung in Aktivmatrix-Displays mit hohen Kontrastwerten
AU7514700A (en) 1999-09-07 2001-04-10 Syngenta Participations Ag Cyanopiperidines
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
AU2001236698A1 (en) 2000-02-07 2001-08-14 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
CN1234358C (zh) 2000-06-21 2006-01-04 弗·哈夫曼-拉罗切有限公司 苯并噻唑衍生物
AR028782A1 (es) 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
US7060331B2 (en) 2000-07-13 2006-06-13 Merck Patent Gmbh Chiral compounds 1
US6723730B2 (en) 2000-07-20 2004-04-20 Neurogen Corporation Capsaicin receptor ligands
AU2001276645A1 (en) 2000-10-18 2002-04-29 Pfizer Products Inc. Combination of statins and sorbitol dehydrogenase inhibitors
PT1337271E (pt) 2000-11-30 2005-01-31 Pfizer Prod Inc Combinacao de agonistas de gaba e inibidores de sorbitol desidrogenase
US7193113B2 (en) 2000-12-15 2007-03-20 Japan Science And Technology Corporation Arylbis(perfluoroalkylsulfonyl) methane and metallic salt thereof, and methods for producing the same
US20030232996A1 (en) 2001-04-20 2003-12-18 Brown David L Regioselective synthesis of 3,4-di{(carboclyl or heterocyclyl)thiophenes
EP1408986B1 (en) 2001-05-08 2008-09-24 Yale University Proteomimetic compounds and methods
US20040038982A1 (en) 2001-07-13 2004-02-26 Bondinell William E. Compounds and methods
JP2003095951A (ja) 2001-09-25 2003-04-03 Sumitomo Pharmaceut Co Ltd 慢性関節リウマチ治療剤
EP1437344A4 (en) 2001-09-28 2006-09-20 Takeda Pharmaceutical BENZOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
WO2003053922A2 (en) 2001-12-19 2003-07-03 Merck & Co., Inc. Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
US20050119251A1 (en) 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
JP2003192673A (ja) 2001-12-27 2003-07-09 Bayer Ag ピペラジンカルボキシアミド誘導体
ES2345044T3 (es) 2002-02-01 2010-09-14 Euro-Celtique S.A. 2-piperazin-piridinas utiles para tratar el dolor.
DE60325025D1 (de) 2002-02-15 2009-01-15 Glaxo Group Ltd Modulatoren des vanilloidrezeptors
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
PL212089B1 (pl) 2002-03-13 2012-08-31 Janssen Pharmaceutica Nv Związki heterocykliczne jako inhibitory deacetylazy histonowej, kompozycja farmaceutyczna je zawierająca, ich zastosowanie, sposób wytwarzania, sposób wykrywania lub identyfikacji HDAC oraz kompozycja
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
CN1150176C (zh) 2002-05-22 2004-05-19 上海医药工业研究院 芳烷酮哌嗪衍生物及其应用
WO2003099266A2 (en) 2002-05-23 2003-12-04 Abbott Laboratories Acetamides and benzamides that are useful in treating sexual dysfunction
EP1522314B1 (en) 2002-06-26 2014-03-05 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
CA2491079C (en) 2002-06-28 2011-10-04 Donald J. Kyle Therapeutic piperazine derivatives useful for treating pain
EP1388538B1 (en) 2002-07-09 2010-09-01 Merck Patent GmbH Polymerisation Initiator
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
AU2003256922A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted heterocyclic compounds as modulators of the ccr5 receptor
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
BR0314761A (pt) 2002-09-27 2005-07-26 Sumitomo Pharma Composto de adenina e seu uso
EP1551811A1 (en) 2002-10-17 2005-07-13 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US7452555B2 (en) 2003-01-21 2008-11-18 S.S.C.I., Inc. Cocrystallization
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
DE10311065A1 (de) 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
CA2526361C (en) 2003-05-20 2012-05-15 Ajinomoto Co., Inc. Amide derivative
AR044688A1 (es) 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
US20050009841A1 (en) 2003-07-11 2005-01-13 Zheng Guo Zhu Novel amides useful for treating pain
US7129235B2 (en) 2003-07-11 2006-10-31 Abbott Laboratories Amides useful for treating pain
EP2080757A1 (en) 2003-07-24 2009-07-22 Euro-Celtique S.A. Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
PL1867644T3 (pl) 2003-07-24 2009-10-30 Euro Celtique Sa Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
CN101914088A (zh) 2003-07-24 2010-12-15 尤罗塞尔蒂克股份有限公司 哌啶化合物和含有它们的药物组合物
WO2005011654A2 (en) 2003-07-29 2005-02-10 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
CA2533901A1 (en) 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
KR20060036106A (ko) 2003-07-30 2006-04-27 제논 파마슈티칼스 인크. 피리딜 유도체 및 그의 치료제로서의 용도
NZ545265A (en) 2003-07-30 2009-11-27 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use for treating diseases mediated by stearoyl-CoA desaturase (SCD) enzymes
US7514436B2 (en) 2003-07-30 2009-04-07 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
CN1832935A (zh) 2003-08-01 2006-09-13 欧洲凯尔特公司 用于治疗疼痛的治疗药
EP2426120A1 (en) 2003-08-18 2012-03-07 Fujifilm Finechemicals Co., Ltd. Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them
ATE412646T1 (de) 2003-09-22 2008-11-15 Euro Celtique Sa Zur behandlung von schmerzen geeignete therapeutische mittel
DK1664041T3 (da) 2003-09-22 2008-10-27 Euro Celtique Sa Phenylcarboxamidforbindelser, der er egnede til behandling af smerter
WO2005037284A1 (en) 2003-10-15 2005-04-28 Pfizer Products Inc. Sorbitol dehydrogenase inhibitor and hypertensive agent combinations
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
AU2004312398B8 (en) 2003-12-30 2008-10-09 Euro-Celtique S.A. Piperazines useful for treating pain
US7355045B2 (en) 2004-01-05 2008-04-08 Applera Corporation Isotopically enriched N-substituted piperazine acetic acids and methods for the preparation thereof
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
MX2007003321A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
AU2005286653A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-CoA-desaturase
CN101083994A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其用作硬脂酰CoA去饱和酶抑制剂的用途
AU2005329423A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP1828258B1 (en) * 2004-11-09 2010-06-30 Basf Se N-substituted imides as polymerization initiators
US20060116368A1 (en) 2004-11-29 2006-06-01 Calvo Raul R 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor
GT200600046A (es) 2005-02-09 2006-09-25 Terapia de combinacion
CN101142194B (zh) 2005-03-14 2012-10-10 顶点制药有限责任公司 吲哚衍生物,组合物及用作β-分泌酶抑制剂的方法
DE102005014904A1 (de) 2005-03-26 2007-02-01 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
FR2884516B1 (fr) 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
CN101296914B (zh) 2005-08-26 2012-07-18 盐野义制药株式会社 具有ppar激动活性的衍生物
KR101289995B1 (ko) 2005-09-27 2013-07-26 시오노기 앤드 컴파니, 리미티드 Pgd2 수용체 길항제 활성을 갖는 설폰아마이드 유도체
US20070155707A1 (en) 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
JP2009523747A (ja) 2006-01-18 2009-06-25 シエナ ビオテク ソシエタ ペル アチオニ α7ニコチン性アセチルコリン受容体のモジュレーターおよびその治療上の使用
CN101490017B (zh) 2006-02-28 2013-01-23 海利空医疗公司 作为pde4抑制剂的用于治疗的哌嗪类
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
TW200815426A (en) 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
WO2008005368A2 (en) 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
JP2010510201A (ja) 2006-11-20 2010-04-02 グレンマーク・ファーマシューティカルズ・エスエー ステアリン酸CoA脱飽和酵素阻害剤としてのアセチレン誘導体
DE102006060598A1 (de) 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
KR20090130065A (ko) 2007-04-13 2009-12-17 수퍼젠, 인크. 암 또는 과증식성 장애 치료에 유용한 Axl 키나제 억제제
JP5462784B2 (ja) * 2007-04-27 2014-04-02 パーデュー、ファーマ、リミテッド、パートナーシップ Trpv1アンタゴニストとその使用
AU2008246202B2 (en) 2007-04-27 2011-12-01 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US8058299B2 (en) 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
WO2008147864A2 (en) 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
AU2008287542C1 (en) 2007-06-01 2015-01-22 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
CA2687217A1 (en) 2007-06-13 2008-12-24 Northeastern University Antibiotic compounds
EP2170845A1 (en) 2007-06-28 2010-04-07 Intervet International BV Substituted piperazines as cb1 antagonists
US8420680B2 (en) 2007-06-29 2013-04-16 Emory University NMDA receptor antagonists for neuroprotection
US20100261723A1 (en) 2007-07-09 2010-10-14 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009023539A2 (en) 2007-08-09 2009-02-19 Abbott Laboratories Tetrahydropyridine carboxamide derivatives as trpvl antagonists
US7994174B2 (en) 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
WO2009045382A1 (en) 2007-10-04 2009-04-09 Merck & Co., Inc. Substituted aryl sulfone derivatives as calcium channel blockers
US8569282B2 (en) 2007-12-11 2013-10-29 Cytopathfinder, Inc. Carboxamide compounds and their use
US7935817B2 (en) 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
JP2009249346A (ja) 2008-04-08 2009-10-29 Fujifilm Corp ピリジン骨格を有する血液脳関門透過性化合物
WO2009155116A2 (en) 2008-05-30 2009-12-23 Georgetown University Methods of reducing pain and inflammation
UA99540C2 (ru) 2008-07-21 2012-08-27 Пердью Фарма Л.П. Замещенные мостиковым хиноксалином пиперидиновые соединения и их применение
US8546388B2 (en) 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
US8759362B2 (en) 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8703962B2 (en) 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
EP2414348B1 (en) 2009-04-03 2013-11-20 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
EP2576539B1 (de) 2010-05-27 2017-12-13 Bayer CropScience AG Pyridinylcarbonsäure derivate als fungizide
WO2011162409A1 (en) 2010-06-22 2011-12-29 Shionogi & Co., Ltd. Compounds having trpv1 antagonistic activity and uses thereof
WO2012047764A1 (en) 2010-10-04 2012-04-12 Intermune, Inc. Therapeutic antiviral peptides
EP2630134B9 (en) 2010-10-20 2018-04-18 Pfizer Inc Pyridine-2- derivatives as smoothened receptor modulators
EP2635571B1 (en) 2010-11-04 2015-08-12 Theravance Biopharma R&D IP, LLC Novel inhibitors of hepatitis c virus
UY33817A (es) 2010-12-21 2012-07-31 Boehringer Ingelheim Int ?nuevas oxindolpirimidinas bencílicas?.
US20120202794A1 (en) 2011-01-24 2012-08-09 Pharmasset, Inc. Compounds
WO2012117421A1 (en) 2011-03-02 2012-09-07 Orchid Research Laboratories Ltd Histone deacetylase inhibitors
CN102336720B (zh) 2011-03-02 2016-01-13 华中科技大学 2-氨基噻唑衍生物及制备方法和应用
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
EP2709609B1 (en) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterocyclic compounds
PT2723732T (pt) 2011-06-22 2017-02-17 Purdue Pharma Lp Antagonistas de trpv1 incluindo substituinte di-hidroxilo e suas utilizações
US20140155419A1 (en) 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
US9394293B2 (en) 2011-08-10 2016-07-19 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
WO2013066831A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
WO2013110134A1 (en) 2012-01-25 2013-08-01 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds and methods for their use
US20150126519A1 (en) 2012-03-20 2015-05-07 Fred Hutchinson Cancer Research Center Antibiotic compounds and compositions, and methods for identification thereof
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
MX2014013752A (es) 2012-05-11 2014-12-08 Abbvie Inc Inhibidores de nampt.
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
SI2723732T1 (sl) 2017-05-31
KR20150055094A (ko) 2015-05-20
US20160222002A1 (en) 2016-08-04
ME02609B (me) 2017-06-20
PT2723732T (pt) 2017-02-17
JP5699251B2 (ja) 2015-04-08
CY1119111T1 (el) 2018-02-14
CN103717594A (zh) 2014-04-09
WO2012176061A1 (en) 2012-12-27
CN105693712A (zh) 2016-06-22
JP2014520139A (ja) 2014-08-21
UA113288C2 (xx) 2017-01-10
EP2723732B1 (en) 2017-01-18
CN103717594B (zh) 2016-12-14
PL2723732T3 (pl) 2017-07-31
AU2012273652A1 (en) 2013-05-02
MX2014000344A (es) 2015-09-23
US10450308B2 (en) 2019-10-22
ES2620528T3 (es) 2017-06-28
US9630959B2 (en) 2017-04-25
RU2014101255A (ru) 2015-07-27
US20200239460A1 (en) 2020-07-30
HRP20170507T1 (hr) 2017-06-02
NZ618912A (en) 2015-07-31
MX354015B (es) 2018-02-08
EP3173411B1 (en) 2018-05-09
SG195136A1 (en) 2013-12-30
BR112013032658A2 (pt) 2017-11-07
CO6852081A2 (es) 2014-01-30
AR086709A1 (es) 2014-01-15
WO2012176061A8 (en) 2013-08-08
HUE031372T2 (en) 2017-07-28
US20140329829A1 (en) 2014-11-06
TWI453205B (zh) 2014-09-21
WO2012176061A9 (en) 2013-03-14
IL229817A (en) 2016-04-21
CA2837178C (en) 2016-09-20
KR20140022469A (ko) 2014-02-24
US20170183337A1 (en) 2017-06-29
ZA201400419B (en) 2015-04-29
RU2621708C2 (ru) 2017-06-07
PE20141531A1 (es) 2014-10-23
AU2012273652B2 (en) 2015-09-03
RS55701B1 (sr) 2017-07-31
MY185061A (en) 2021-04-30
CA2837178A1 (en) 2012-12-27
EP3173411A1 (en) 2017-05-31
KR101589837B1 (ko) 2016-01-29
US9273043B2 (en) 2016-03-01
SG10201605163PA (en) 2016-08-30
DK2723732T3 (en) 2017-04-03
EP2723732A1 (en) 2014-04-30
LT2723732T (lt) 2017-02-27
TW201313707A (zh) 2013-04-01

Similar Documents

Publication Publication Date Title
TN2015000429A1 (en) 3-acetylamino-1-(phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino)benzene derivatives for the treatment of hyperproliferative disorders
EP3331880A4 (en) N- (PYRIDIN-2-YL) -4- (THIAZOL-5-YL) PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS
HK1207077A1 (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol- 3-yl]-4-(4-methyl piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)- benzamide n-[5-(35--)-1h--3-]-4-(4---1-)-2-(- -4-)-
IL245882A0 (en) A process for the preparation of n-[(3-aminooxan-3-yl)methyl]-2-(1,1-dioxo-5,3-dihydro-4,1-benzothiazen-4-yl)-6-methylquinazoline- 4-Amin
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
BR112014010183A2 (pt) composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou uma condição de doença mediada por uma fgfr cinase
UA103319C2 (en) Thiazole- and oxazole-benzene sulfonamide compounds
CL2015001537A1 (es) Compuestos derivados de piridin-2-amidas agonistas cb2; proceso de sintesis; composicion farmaceutica; uso en el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, glaucoma, diabetes mellitus, entre otras.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
EP2566859A4 (en) PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
CL2015001536A1 (es) Compuestos derivados de piridina, agonistas del receptor de canabinoides 2; proceso de sintesis; su uso para el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, infarto de miocardio, apoplejia, entre otras.
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
CL2013003550A1 (es) Compuestos derivados de (s)-n-(benzo-[d]-tiazol-2-il)-4-(5-(1,2-dihidroxietil)-piridin-2-il)-piperazin-1-carboxamida sustituidas; antagonistas de trpv1; composición farmacéutica; un producto de combinación; útiles para el tratamiento del dolor, osteoartritis, iu, úlcera, ibd ó ibs.
AP2014007436A0 (en) A novel 1,2,3,4,-Tetrahydroquinoline derivative useful for the treatment of diabetes
PH12016501619A1 (en) Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
ZA201804387B (en) Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
PH12019500467A1 (en) Benzo-fused heterocyclic derivatives useful agonists of gpr120
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
HRP20190349T1 (hr) Oralni pripravci za liječenje gastroezofagealne refluksne bolesti
EP3303323A4 (en) 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists
MX2010002007A (es) Sulfonas ciclicas sustituidas por amino-bencilo utiles como inhibidores de bace.
NZ702239A (en) Heteroaryl compounds and methods of use thereof
WO2014195977A3 (en) Novel polymorphs of vismodegib